RYLD vs XBI
Global X Russell 2000 Covered Call ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.60% for RYLD.
- • RYLD pays a higher dividend yield (7.22%).
Side-by-side metrics
| Metric | RYLD | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.60% | 0.35% |
Dividend yield Trailing 12-month yield. | 7.22% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $1.30B | $10.92B |
YTD return | 11.59% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.52 | 1.01 |
P/E ratio | 16.46 | — |
Last price | $15.48 | $156.41 |
Inception | — | — |
Issuer | Global X | State Street |
RYLD top holdings
| RSSL | Global X Russell 2000 ETF | 102.97% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About RYLD
RYLD (Global X Russell 2000 Covered Call ETF) is Russell 2000 covered call strategy for income. Managed by Global X, the fund carries $1.3B in assets under management, an expense ratio of 0.60%, a dividend yield of 7.22%. Its largest holding is Global X Russell 2000 ETF (RSSL), which represents 103.0% of the portfolio. Real Estate is the fund's largest sector exposure at 6.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.